進階篩選 ›

SNS-314 Mesylate

貨號 Cat. No.
S1154
規格 Size
5~200mg
品牌 Brand
Selleckchem

Description


SNS-314 Mesylate
Catalog No.S1154
 

1 Reviews2 Product Citations

SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.


















Size Price Stock Quantity  


































10mM/1mLIn DMSO USD 315 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
5mg USD 151 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
10mg USD 264 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
50mg USD 844 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
200mg USD 2356 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 




 Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw


Biological Activity







































Description SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.
Targets Aurora A Aurora B Aurora C      
IC50 9 nM 31 nM 3.4 nM [1]      
In vitro In HCT116 colorectal carcinoma cell line, with intact or depleted p53 protein levels, SNS-314 Mesylate shows enhanced efficacy when administered sequentially with other standard chemotherapeutic agents and the most profound synergies are identified for agents that activate the spindle assembly checkpoint, e.g., docetaxel and vincristine. [2] A recent study shows that SNS-314 Mesylate shows potent antiproliferative activity in HCT116 cells and inhibits soft agar colony formation. [3]
In vivo The sequential treatment with SNS-314 Mesylate followed by docetaxel 24 hours later produces a significant 72.5% tumor growth inhibition of HCT116 xenografts, while docetaxel and SNS-314 Mesylate as single agents produce no significant inhibition of HCT116 tumor growth. [2] In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 Mesylate results a dose-dependent inhibition of histone H3 phosphorylation, indicating effective Aurora-B inhibition in vivo. In addition, HCT116 tumors from animals treated with SNS-314 Mesylate exhibits potent and sustained responses including reduction of phosphorylated histone H3 levels, increased caspase-3 and appearance of increased nuclear size. [3]
Features  

Protocol(Only for Reference)


Kinase Assay: [1]









Aurora-A Kinase Assay Humanized mouse Aurora A (amino acids 107-403) is expressed in E. coli as described previously. For IC50 assays, compounds are titrated three-fold in DMSO and diluted 12.5-fold into assay buffer (10 mM Tris HCl pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.01% Tween-20, and 0.1% BSA). Compounds are then diluted 4-fold into assay buffer containing Aurora A and FAM-PKAtide at final concentrations of 2 nM and 50 nM, respectively. The kinase reaction is initiated by adding ATP in assay buffer at a final concentration of 10 mM and incubated at 21 °C for 25 minutes. As a positive control, DMSO is added instead of compound and as a negative control assay buffer is added instead of Aurora A. Both control reactions are conducted in triplicate. To detect phosphorylated PKAtide, the kinase reaction is combined with Progressive Binding Solution (1:400 Progressive Binding Reagent, 1 × Buffer A, Molecular Devices) in a 1:3 ratio. The mixture is incubated for 30 minutes at 21 °C and the plate is scanned on an Analyst AD with excitation at 485 nm and emission at 530 nm. The percent relative enzymatic activity is calculated by normalizing the mP value for each well to the average positive control. Relative enzymatic activity values are plotted as a function of the logarithm of compound concentration and IC50 values are generated in GraphPad Prism software using a sigmoidal dose-response curve-fit. IC50’s are calculated as the concentration of compound at which enzymatic activity i

Cell Assay: [2]





















Cell lines HCT116 SCR and HCT116 p53 RNAi cells
Concentrations ~125 nM
Incubation Time 48 hours
Method Viability is measured using the CellTiter-Blue cell viability assay. Cells are treated as described above, although with a 5-day incubation period. Cytotoxicity is determined by measuring intracellular ATP using the CellTiter-Glo Luminescence Cell Viability Assay. Cells are seeded in white 96-well tissue culture plates at a density of 1.5-2 × 103 cells/well, and a serial dilution of SNS-314 is dosed in combination with fixed concentrations of either docetaxel or vincristine for a total of 72 hours. Viability is determined as the ratio between the ATP in treated cells versus control cells. Apoptosis is measured using the caspase-Glo 3/7 system. Cells are plated in white 96-well plates as described above and treated first with SNS-314 for 24 hours, washed with 200 μL of 1× PBS, and fresh medium is added with the second agent for 24 hours.

Animal Study: [2]





















Animal Models HCT116 cells are injected s.c. into the right flank of nu/nu mice.
Dosages ≤42.5 mg/kg
Administration Administered via i.p.
Solubility 15% Captisol, 30 mg/mL

1


References


Chemical Information


Download SNS-314 Mesylate SDF


 

















Molecular Weight (MW) 527.04
Formula

C18H15ClN6OS2.CH4O3S
CAS No. 1146618-41-8















Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A

 


























Solubility (25°C) * In vitro DMSO 105 mg/mL (199 mM)
Water 6 mg/mL (11 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 15% Captisol, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.


 








Chemical Name M1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea Mesylate

 

Preparing Stock Solutions



















Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.52704 5.2704 10.5408 15.8112

Molarity Calculator Dilution Calculator Molecular Weight Calculator

Customer Reviews (1)




































Click to enlarge		 Rating

 
Source Dr. Zhang of Tianjin Medical University. SNS-314 Mesylate purchased from Selleck
Method Western blot
Cell Lines MDA-231 cells
Concentrations 0-10 μM
Incubation Time  
Results SNS-314 treatment resulted in a reduction of Histone H3 and Aurora A/B/C phosphorylation.


 

Product Citations (2)




 


 

詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢